Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.68 |
| ▸ | SYK | P43405 | 6/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | STK16 | O75716 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | PAK4 | O96013 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | LTK | P29376 | 1/20 | 0.60 |
| ▸ | TTK | P33981 | 1/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.60 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.60 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709851 | 0.88 | SYK (0.57) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL1709923 | 0.84 | SYK (0.61) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL1709847 | 0.82 | SYK (0.58) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL1709928 | 0.81 | SYK (0.58) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL1709925 | 0.81 | SYK (0.58) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL3711035 | 0.81 | SYK (0.58) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL3703626 | 0.80 | SYK (0.56) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL1709757 | 0.80 | SYK (0.56) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL3700980 | 0.80 | SYK (0.56) | MERTKSYKDAPK3JAK2STK16 | |
| SCHEMBL3715160 | 0.79 | ADORA3 (0.59) | SYKDAPK3JAK2STK16MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | claimed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012048222-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | MERTK 993/4885SYK 1176/4885DAPK3 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.